Galacto-oligosaccharide Composition for Inflammatory Bowel Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inflammatory bowel disease (IBD) poses a significant health challenge due to its association with intestinal inflammation, leaky gut syndrome, and metabolic changes, with existing treatments often relying on chemical or biological agents that may not adequately address the underlying gut environment issues.
Innovation Solution
A pharmaceutical and food composition comprising high-purity galacto-oligosaccharides, specifically with a purity of 70% or higher, which includes monosaccharides, disaccharides, trisaccharides, and tetrasaccharides, promotes the growth of beneficial intestinal bacteria and production of short-chain fatty acids, thereby reducing inflammation and improving the intestinal environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemical synthetic agents or biological agents are used to treat inflammatory bowel disease, then inflammatory symptoms can be suppressed, but the underlying gut environment issues and intestinal mucosa damage cannot be adequately addressed
Solution Approach 1:
The patent uses galacto-oligosaccharides to convert the harmful leaky gut condition into a beneficial state by promoting the growth of beneficial bacteria that produce butyric acid, which then repairs the intestinal mucosa and tightens junctions, transforming the damaged gut environment into a healthy one
Solution Approach 2:
The patent introduces galacto-oligosaccharides as an intermediary substance that mediates between the existing gut environment and the desired healthy state by serving as a substrate for beneficial bacteria to produce butyric acid, which then acts on the intestinal mucosa to repair damage
2Adaptability or versatility
If Western dietary patterns are adopted, then modern lifestyle requirements are met, but the composition of gut microbiota changes leading to deterioration of gut environment
Solution Approach 1:
The patent changes the nutritional parameter by introducing galacto-oligosaccharides as a specific prebiotic substrate that selectively promotes the growth of beneficial bacteria, thereby altering the gut microbiota composition from a Western-diet-induced dysbiotic state to a healthy state without requiring complete dietary overhaul
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The galacto-oligosaccharide composition effectively inhibits myeloperoxidase activity, suppresses inflammatory cytokines, reduces disease activity index, and promotes the production of butyric acid, demonstrating anti-inflammatory effects and improving gut health in IBD patients.
Implementation Method 1
promotes the growth of beneficial intestinal bacteria and production of short-chain fatty acids
Implementation Method 2
promotes the production of butyric acid, demonstrating anti-inflammatory effects
Data Source
AI summary
The present disclosure relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising a galacto-oligosaccharide as an active ingredient. The galacto-oligosaccharide composition of the present disclosure has an anti-inflammatory effect of ameliorating DAI and reducing the levels of inflammatory cytokines and MPO in inflammatory bowel disease model mice, and thus can be effectively used as a drug or food for the prevention, amelioration or treatment of inflammatory bowel disease.